INTCHAINS GROUP LTD-ADR (ICG)

US45828E1047 - ADR

6.392  -0.42 (-6.14%)

Fundamental Rating

4

Taking everything into account, ICG scores 4 out of 10 in our fundamental rating. ICG was compared to 108 industry peers in the Semiconductors & Semiconductor Equipment industry. While ICG has a great health rating, there are worries on its profitability. ICG is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

ICG had negative earnings in the past year.
ICG had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ICG reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: ICG reported negative operating cash flow in multiple years.

1.2 Ratios

ICG has a Return On Assets of -2.74%. This is in the lower half of the industry: ICG underperforms 61.11% of its industry peers.
Looking at the Return On Equity, with a value of -2.82%, ICG is doing worse than 60.19% of the companies in the same industry.
Industry RankSector Rank
ROA -2.74%
ROE -2.82%
ROIC N/A
ROA(3y)36.05%
ROA(5y)23.84%
ROE(3y)37.68%
ROE(5y)24.45%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 11.10%, ICG is doing worse than 89.81% of the companies in the same industry.
ICG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ICG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 11.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-42.25%
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

ICG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ICG has been increased compared to 1 year ago.
ICG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ICG has an Altman-Z score of 62.05. This indicates that ICG is financially healthy and has little risk of bankruptcy at the moment.
ICG has a Altman-Z score of 62.05. This is amongst the best in the industry. ICG outperforms 98.15% of its industry peers.
There is no outstanding debt for ICG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 62.05
ROIC/WACCN/A
WACC11.47%

2.3 Liquidity

A Current Ratio of 28.32 indicates that ICG has no problem at all paying its short term obligations.
ICG has a Current ratio of 28.32. This is amongst the best in the industry. ICG outperforms 100.00% of its industry peers.
ICG has a Quick Ratio of 26.83. This indicates that ICG is financially healthy and has no problem in meeting its short term obligations.
ICG has a better Quick ratio (26.83) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 28.32
Quick Ratio 26.83

5

3. Growth

3.1 Past

ICG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -107.43%.
The Revenue for ICG has decreased by -82.64% in the past year. This is quite bad
The Revenue has been growing by 14.62% on average over the past years. This is quite good.
EPS 1Y (TTM)-107.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.49%
Revenue 1Y (TTM)-82.64%
Revenue growth 3Y14.62%
Revenue growth 5YN/A
Sales Q2Q%5.2%

3.2 Future

Based on estimates for the next years, ICG will show a very strong growth in Earnings Per Share. The EPS will grow by 214.08% on average per year.
The Revenue is expected to grow by 146.80% on average over the next years. This is a very strong growth
EPS Next Y276.55%
EPS Next 2Y214.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year247.21%
Revenue Next 2Y146.8%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

1

4. Valuation

4.1 Price/Earnings Ratio

ICG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 408.23, ICG can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ICG is valued a bit more expensive than 69.44% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.22. ICG is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 408.23

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ICG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as ICG's earnings are expected to grow with 214.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y214.08%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

ICG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

INTCHAINS GROUP LTD-ADR

NASDAQ:ICG (9/6/2024, 8:20:29 PM)

6.392

-0.42 (-6.14%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap383.59M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 408.23
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.74%
ROE -2.82%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 11.1%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 28.32
Quick Ratio 26.83
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-107.43%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y276.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-82.64%
Revenue growth 3Y14.62%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y